Therapeutic drug monitoring: Toward tailored dosing of adalimumab in rheumatoid arthritis.
- Conditions
- rheumatoid arthritisadalimumabtherapeutic drug monitoring
- Registration Number
- NL-OMON29559
- Lead Sponsor
- ReumafondsReade, centrum voor revalidatie en reumatologie
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 102
Inclusion Criteria
1. RA according to the ACR 1987 criteria;
2. Adalimumab treatment for at least 28 weeks;
Exclusion Criteria
Scheduled surgery in the next 6 months or other pre planned reasons for treatment discontinuation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Similar deltaDAS28 in patients with high serum adalimumab concentrations who are randomly assigned to continuation of the regular dose or to dose interval prolongation.
- Secondary Outcome Measures
Name Time Method Cost-effectiveness of therapeutic drug monitoring in rheumatoid arthritis patients responding to adalimumab.